Portal de investigación
Radium-223 international early access program: results from the Spanish subset
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Carles, J
- Mendez, MJ
- Pinto, A
- Saez, MI
- Arranz, JA
- Maroto, P
- Lopez-Criado, P
- Mellado, B
- Donas, JG
- Hernando, S
- Leon, L
- del Alba, AG
- Lainez, N
- Esteban, E
- Perez-Gracia, JL
- Germa, JR
- Lopez-Brea, M
- Perez-Valderrama, B
- Moretones, C
- Castellano, D
Grupos
Abstract
Aim: To report results from the Spanish subset included in the radium-223 international early access program (iEAP). Patients & methods: Ninety patients with castration-resistant prostate cancer and bone metastases received radium-223 55 kBq/kg every 4 weeks for six cycles. Results: The median time to disease progression was 8 months and to prostate-specific antigen progression was 4 months. The percentage of patients with >= 50% confirmed declines in prostate-specific antigen was 9%. The median overall survival was 14 months. Grade 3 or 4 treatment emergent adverse events (TEAEs) occurred in 34% of patients (serious TEAEs 28%, TEAEs leading to discontinuation 27%). Conclusion: Outcomes of the Spanish subset are consistent with the iEAP. Radium-223 was generally well tolerated with no safety concerns.
Datos de la publicación
- ISSN/ISSNe:
- 1479-6694, 1744-8301
- Tipo:
- Article
- Páginas:
- 41-50
- Factor de Impacto:
- 0,797 SCImago ℠
- Cuartil:
- Q2 SCImago ℠
FUTURE ONCOLOGY FUTURE MEDICINE LTD
Citas Recibidas en Web of Science: 2
Documentos
- No hay documentos
Filiaciones
Keywords
- bone metastasis; castration-resistant prostate cancer; radium-223; safety; survival
Proyectos asociados
ESTUDIO RETROSPECTIVO DEL MANEJO DE PACIENTES CON CANCER DE PROSTATA HORMONORESISTENTE AVANZADO. ESTUDIO ESPRO.
Investigador Principal: GASPAR REYNES MUNTANER
SAN-DOC-2010-02 . 2011
ENSAYO CLÍNICO FASE II PILOTO, ABIERTO, MULTICÉNTRICO Y PROSPECTIVO PARA EVALUAR LA SEGURIDAD Y EFICACIA DE PF299804, UN INHIBIDOR PAN-HER IRREVERSIBLE, EN PACIENTES CON GLIOBLASTOMA RECURRENTE CON AMPLIFICACIÓN DE EGFR O PRESENCIA DE LA MUTACIÓN EGFRVIII .
Investigador Principal: GASPAR REYNES MUNTANER
GEINO-11 . 2012
ENSAYO CLINICO, FASE II ALEATORIZADO DE TRATAMIENTO NEO-ADYUVANTE CON DOS CICLOS DE TEMOZOLOMIDA A DOSIS EXTENDIDAS, PREVIOS AL TRATAMIENTO CON TEMOZOLOMIDA MAS IRRADIACION Y POSTERIOR ADYUVANCIA CON TEMOZOLOMIDA VERSUS MISMO TRATAMIENTO CON BEVACIZUMAB
Investigador Principal: GASPAR REYNES MUNTANER
GENOM-009 . 2010
Cita
Carles J,Mendez MJ,Pinto A,Saez MI,Arranz JA,Maroto P,Lopez P,Mellado B,Donas JG,Hernando S,Leon L,del Alba AG,Lainez N,Esteban E,Reynes G,Perez JL,Germa JR,Lopez M,Perez B,Moretones C,Castellano D. Radium-223 international early access program: results from the Spanish subset. Future Oncol. 2018. 14. (1):p. 41-50. IF:2,279. (3).